Skip Navigation


JAC Advance Access originally published online on July 26, 2005
Journal of Antimicrobial Chemotherapy 2005 56(3):602-603; doi:10.1093/jac/dki274
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
56/3/602    most recent
dki274v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gleeson, T.
Right arrow Articles by Mascola, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gleeson, T.
Right arrow Articles by Mascola, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Correspondence

Successful treatment of Acinetobacter meningitis with meropenem and rifampicin

Todd Gleeson1,*, Kyle Petersen1 and John Mascola2

1 Department of Infectious Diseases, National Naval Medical Center, 8901 Wisconsin Avenue, Bethesda, MD 20889–5600, USA; 2 Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892, USA

* Corresponding author. Tel: +1-301-319-8360; Fax: +1-301-295-2992; E-mail: tdgleeson@bethesda.med.navy.mil

Keywords: nosocomial meningitis , post-neurosurgical meningitis , ventriculostomy

The first 10% of the full text of this article appears below.

Sir,

Acinetobacter calcoaceticus-baumannii complex is a common cause of nosocomial infections, including post-neurosurgical meningitis. Multidrug-resistant (MDR) Acinetobacter is increasingly common worldwide, presenting a therapeutic challenge. Non-traditional antibiotics, including sulbactam, colistin and polymyxin B, have been used for MDR Acinetobacter meningitis.

Rifampicin demonstrates a bactericidal effect against Acinetobacter baumannii both in vitro as well as in animal models. Rifampicin . . . [Full Text of this Article]

Transparency declarations


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
A. Rodriguez Guardado, A. Blanco, V. Asensi, F. Perez, J. C. Rial, V. Pintado, E. Bustillo, M. Lantero, E. Tenza, M. Alvarez, et al.
Multidrug-resistant Acinetobacter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments
J. Antimicrob. Chemother., April 1, 2008; 61(4): 908 - 913.
[Abstract] [Full Text] [PDF]